Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing

Gonzalez et al. use a viral evolutionary approach to generate cross-species compatible AAV (ccAAVs) vectors. They describe a highly potent new variant, AAV.cc47, with enhanced transduction efficiency over AAV serotype 9 and show its efficacy in different mouse models, pigs and non-human primates. Recombinant adeno-associated viral (AAV) vectors are a promising gene delivery platform, but ongoing clinical trials continue to highlight a relatively narrow therapeutic window. Effective clinical translation is confounded, at least in part, by differences in AAV biology across animal species. Here, we tackle this challenge by sequentially evolving AAV capsid libraries in mice, pigs and macaques. We discover a highly potent, cross-species compatible variant (AAV.cc47) that shows improved attributes benchmarked against AAV serotype 9 as evidenced by robust reporter and therapeutic gene expression, Cre recombination and CRISPR genome editing in normal and diseased mouse models. Enhanced transduction efficiency of AAV.cc47 vectors is further corroborated in macaques and pigs, providing a strong rationale for potential clinical translation into human gene therapies. We envision that ccAAV vectors may not only improve predictive modeling in preclinical studies, but also clinical translatability by broadening the therapeutic window of AAV based gene therapies.

Automated summary

Researchers have successfully generated a cross-species compatible AAV (ccAAVs) vector using a viral evolutionary approach, and discovered a highly potent new variant AAV.cc47. AAV.cc47 demonstrated enhanced transduction efficiency compared to AAV serotype 9 in mouse, pig, and non-human primate models, showing great potential for gene therapy. This study focuses on investigating cross-species delivery of AAV and provides new theoretical insights for translating gene therapy into clinical applications.